The AJOL web site will be undergoing some maintenance today from 18h00 (BMT) onwards. There will temporarily be some restrictions to the available functionality:

Users will not be able register or log in during this period.
full text (PDF) downloads of Open Access journal articles will be available as always
downloads of full text (PDF) subscription based journal articles will NOT be available

The site will also be unavailable for a short while.

We apologise for any inconvenience caused.

Please check back soon, as we will revert to usual policy as soon as possible.

Pan African Medical Journal
Journal / Pan African Medical Journal / Vol. 44 No. 1 (2023) / Articles

download PDF

Published:

Dec 5, 2023

Keywords:

Non-muscle invasive bladder cancer neutrophil/lymphocyte ratio biomarker BCG failure immunotherapy

Issue

Vol. 44 No. 1 (2023)

Section

Articles

Brief summary of the agreement Anyone is free: · to copy, distribute, and display the work; · to make derivative works; · to make commercial use of the work; Under the following conditions: Attribution · the original author must be given credit; · for any reuse or distribution, it must be made clear to others what the license terms of this work are; · any of these conditions can be waived if the authors gives permission. Statutory fair use and other rights are in no way affected by the above

Idriss Ziani

Department of Urological Surgery “A”, Ibn Sina University Hospital of Rabat, Rabat, Morocco; Faculty of Medicine of Rabat, Mohammed V University in Rabat, Morocco

Ahmed Ibrahimi

Department of Urological Surgery “A”, Ibn Sina University Hospital of Rabat, Rabat, Morocco; Faculty of Medicine of Rabat, Mohammed V University in Rabat, Morocco

Youssef Zaoui

Department of Urological Surgery “A”, Ibn Sina University Hospital of Rabat, Rabat, Morocco; Faculty of Medicine of Rabat, Mohammed V University in Rabat, Morocco

Hachem EL Sayegh

Department of Urological Surgery “A”, Ibn Sina University Hospital of Rabat, Rabat, Morocco; Faculty of Medicine of Rabat, Mohammed V University in Rabat, Morocco

Redouane Abouqal

Faculty of Medicine of Rabat, Mohammed V University in Rabat, Morocco; Acute Medical Unit, Ibn Sina University Hospital, Faculty of Medicine and Pharmacy, Rabat, Morocco; Laboratory of Biostatistics, Clinical Research and Epidemiology, Mohammed V University in Rabat, Rabat, Morocco

Yassine Nouini

Department of Urological Surgery “A”, Ibn Sina University Hospital of Rabat, Rabat, Morocco; Faculty of Medicine of Rabat, Mohammed V University in Rabat, Morocco

Amal Bouziane

Faculty of Medicine of Rabat, Mohammed V University in Rabat, Morocco; Laboratory of Biostatistics, Clinical Research and Epidemiology, Mohammed V University in Rabat, Rabat, Morocco; Department of Periodontology, Faculty of Dental Medicine, Mohammed V University in Rabat, Rabat, Morocco

Abstract

Introduction: neutrophil/lymphocyte ratio (NLR), as a biomarker of the systemic inflammatory response, has been studied for diverse tumors. Our study aims to determine whether the NLR can be reliably used as a tool to predict disease course in patients diagnosed with primary non-muscle invasive bladder tumors (NMIBC).

Methods: a retrospective study between 2009 to 2014 was conducted on 300 patients newly diagnosed with NMIBC at our institution. The cut-off value of NLR was set at 2.5. Survival curves were compared using the log-rank test. The association between recurrence, progression, and NLR was assessed univariate, and the prognostic significance of high NLR was assessed using multivariate analysis.

Results: one hundred and seventy-five patients had an NLR <2.5 and 125 patients had an NLR ≥ 2.5. The survival rate with recurrence at 5 years was higher in the group with an NLR >2.5 (p<0.001, 35 vs 18 months), similarly, the survival rate with progression at 5 years was higher in the group with an NLR > 2.5 (p=0.001, 36 vs. 27 months). The failure rate of immunotherapy using BCG was higher when the NLR was over 2.5. In a multivariate analysis, the factors associated with recurrence were NLR>2.5 (HR=2.03, 95% CI=1.32-3.11, p=0.001), pathologic stage pT1 (HR=2.42, 95% CI=1.52-3.85, p=0.001), high-grade (HR=1.76, 95% CI=1.52-3.92, p=0.01), concomitant CIS lesions (HR=2.31, 95% CI=1.36-3.92, p=0.001), presence of lymphovascular emboli (HR=5.77, 95% CI=1.77-18.78, p=0.004), and BCG immunotherapy failure (HR=5.29, 95% CI=2.88-9.70, p=0.001). With regard to progression, in a multivariate study, the significant factors were NLR>2.5(HR=2.91, 95% CI=1.17-7.23, p=0.01), BCG immunotherapy failure (HR=5.68, 95% CI=3.16-10.22, p=0.001), and the presence of lymphovascular emboli (HR=5.01, 95% CI=1.50-16.05, p=0.001).

Conclusion: preoperative NLR value could predict recurrence, progression, and failure of BCG immunotherapy in NMIBC patients.

Journal Identifiers

eISSN: 1937-8688